The administrative stay of execution of the price reduction disposition for AstraZeneca's diabetes drugs Forxiga (dapagliflozin), Xigduo (dapagliflozin+metformin), and Korea United Pharm’s Atmeg Combigel (atorvastatin 10 mg + omega 3) has been extended, and the insurance ceiling price for the drugs will remain unchanged until June 30.

On the 7th, the Ministry of Health and Welfare announced the extension of the stay of execution of these drugs in ‘the drug reimbursement list and reimbursement ceiling price table.’

This is the result of the Seoul Administrative Court's decision to grant AstraZeneca and United Pharmaceuticals Korea's request to suspend enforcement of drug price